That it is the sense of the House of Representatives that— (1) by enacting the Federal Food, Drug, and Cosmetic Act and subsequent amendments, Congress intended for and authorized the Food and Drug Administration to review and approve drug applications under its expert authority; (2) Congress intended the provisions of the Federal Food, Drug, and Cosmetic Act to govern any review of Food and Drug Administration approval decisions to ensure that such decisions are given due deference, are based on scientifically driven assessments made by experts at Food and Drug Administration, and maximize the public’s access to life- and health-preserving medications; (3) Congress did not intend for Federal courts to engage in independent judicial review of the scientific evidence before the Food and Drug Administration and make their own findings about a drug’s safety and efficacy; (4) a Federal court’s attempt to reverse mifepristone’s approval represents a violation of the intent of Congress in passing the Federal Food, Drug, and Cosmetic Act; (5) the stay of mifepristone’s approval by a district court represents a threat to other duly Food and Drug Administration-regulated products; and (6) all people living in the United States should have the ability to make decisions about their own lives, futures, and reproductive health care, including abortion.